We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

U14:SGXUOL Group Limited Analysis

Data as of 2026-03-11 - not real-time

SGD 10.67

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

UOL Group Limited trades at SGD 10.67, comfortably above its 200‑day SMA (8.20) but below the 20‑day SMA (11.01), indicating a short‑term pull‑back within a longer‑term uptrend. Technical signals are mixed: the MACD histogram is negative and the RSI sits at 48, while volume is increasing and the price is holding above the identified support of 10.18. Fundamentally, the company shows solid top‑line strength with 10.6% revenue growth, healthy gross (39.5%) and operating margins (24.6%), and a dividend yield of 1.69% backed by a modest 31.6% payout ratio. The valuation is attractive – a PE of 18.7 versus an industry average of 32.6, a PB of 0.77 and a DCF fair value of SGD 22.54 suggest the stock is undervalued. However, the balance sheet carries a high debt‑to‑equity ratio of 27.9, though cash of SGD 1.25 bn provides a cushion. Overall, the stock presents a compelling value case with decent income, but investors should monitor the near‑term technical weakness and leverage levels.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below 20‑day SMA indicating short‑term weakness
  • Increasing volume supports potential bounce from support level
  • Dividend yield provides downside protection

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervaluation relative to peers (PE 18.7 vs 32.6 industry avg)
  • Consistent revenue growth and strong margin profile
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • DCF fair value of SGD 22.5 suggests significant upside
  • Diversified geographic footprint reduces single‑market exposure
  • Robust operating cash flow and free cash flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin14.90%
P/E Ratio18.7
ROE3.71%
ROA2.19%
Debt/Equity27.90
P/B Ratio0.8
Op. Cash FlowSGD1.3B
Free Cash FlowSGD1.0B
Industry P/E32.6

Technical Analysis

TrendBullish
RSI48.0
SupportSGD 10.18
ResistanceSGD 11.48
MA 20SGD 11.01
MA 50SGD 10.41
MA 200SGD 8.20
MACDBearish
VolumeIncreasing
Fear & Greed Index78.16

Valuation

Fair ValueSGD 22.54
Target PriceSGD 11.68
Upside/Downside9.48%
GradeUndervalued
TypeBlend
Dividend Yield1.69%

Risk Assessment

Beta0.20
Volatility42.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.